7/24 Healthy Brain and Child Development National Consortium

7/24 健康大脑和儿童发展国家联盟

• 批准号: 10750125
• 负责人: JAMES J. PEKAR
• 金额: $ 31.36万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10750125
• 关键词: Administrative Supplement; Alcohols; Anxiety; Behavior; Behavioral; Biological; Birth; Brain; Cannabis; Caregivers; Child; Child Development; Child Health; Childhood; Cognition; Cognitive; Collection; Communities; Complex; Congenital Abnormality; Country; Data Collection; Detection; Development; Discipline of obstetrics; Education; Environment; Environmental Health; Epidemiology; Epigenetic Process; Etiology; Evaluation; Exposure to; Family; Fetal Growth; Fetal Reduction; Fetus; Funding; Generations; Genetic; Goals; Gynecology; Health; Heavy Metals; Helping to End Addiction Long-term; Immune signaling; Individual; Infant Health; Knowledge; Laboratories; Language Delays; Language Development; Life; Link; Longitudinal Studies; Low Birth Weight Infant; Maternal Health; Mediating; Memory impairment; Metabolic; National Institute of Drug Abuse; Neonatal Abstinence Syndrome; Opioid; Outcome; Parents; Participant; Pathogenicity; Personal Satisfaction; Persons; Placenta; Policies; Predisposition; Pregnancy; Pregnant Women; Premature Birth; Prenatal care; Preparation; Prevention; Prevention strategy; Process; Proteins; Protocols documentation; Psychopathology; Psychophysiologic Disorders; Research; Resources; Risk; Sampling; Signaling Protein; Site; Specimen; Structure; Techniques; Tetrahydrocannabinol; Tissue Banks; Tissues; Tobacco; Trauma; Umbilical Cord Blood; Umbilical cord structure; Universities; adverse outcome; alcohol consumption during pregnancy; cohort; emotion regulation; epidemiology study; experience; fetal; fetal opioid exposure; fetal substance exposure; health care service utilization; health equity; in utero; inattention; innovation; interest; longitudinal, prospective study; mRNA Expression; maternal opioid use; multidisciplinary; neonatal health; neuroimaging; nutrition; opioid use; opioid use disorder; opioid use in pregnancy; polysubstance use; pregnant; prenatal; protocol development; racism; response; social; substance use; success; toxicant

PROJECT SUMMARY/ABSTRACT Opioid use during pregnancy is widespread and associated with adverse outcomes for the pregnant individual and the developing child. Prenatal opioid exposure is associated with a wide range of negative fetal and child outcomes including reduced fetal growth, premature birth, lower birth weight, congenital defects, increased neonatal healthcare utilization, and heightened risk for later behavioral (e.g., anxiety, inattention), cognitive (e.g., memory deficits, delayed language acquisition), and metabolic problems. Despite opioid use being linked to adverse maternal, fetal, and child outcomes, the mechanisms through which these arise and the potential consequences of prenatal opioid exposure on child health and development (e.g., brain and behavior) remain largely unexplored. This lack of etiologic knowledge has limited treatment, prevention, and mitigation efforts leaving individuals and families susceptible to reverberating adverse outcomes. The HEALthy Brain and Child Development (HBCD) Study is a 25-site longitudinal prospective study of early child development in the US that will assess a broad spectrum of biological (e.g., neuroimaging, genetics, epigenetics), behavioral (e.g., cognition and emotional regulation), experiential (e.g., trauma), social (e.g., racism), and health (e.g., psychopathology) factors among ~7,500 nationally-representative pregnant women and their children from pregnancy to mid-childhood. A major goal of the HBCD study is to increase understanding of the potential consequences of prenatal substance exposures. It will be enriched for maternal substance use during pregnancy (i.e., ~25% of the sample will be using opioids, cannabis, alcohol, and/or tobacco during pregnancy and 12% of the total sample will be using opioids) and offers a unique opportunity to inform our understanding of how the adverse consequences associated with opioid use during pregnancy arise. Although HBCD will be the largest long-term study of early brain and child development outcomes in the US, the core protocol does not include the collection of delivery biospecimens. This Administrative Supplement in response to the NIDA/ORWH Administrative Supplement Notice of Special Interests: HEAL Initiative: Biospecimen Collection in Pregnancy (NOT-DA-23-005) proposes to leverage the HEALthy Brain and Child Development (HBCD) by expanding the biospecimen collection of the Core HBCD Protocol to include delivery specimens (placenta, cord tissue, cord blood). Delivery samples will be collected from a representative sample of HBCD Study participants across up to 14 sites (and approximately 2,400 participants across HBCD sites submitting applications in response to this NOSI). This will provide an unprecedented resource generating opportunity for a larger scientific community to comprehensively evaluate pathophysiological mechanisms that mediate the connection between opioid and polysubstance use during pregnancy and adverse neonatal, infant, and/or maternal health outcomes and, in turn, inform innovative preventive strategies.

项目摘要/摘要 怀孕期间的阿片类药物使用普遍存在，并与怀孕个人的不良后果有关 和发育中的孩子。产前阿片类药物暴露与广泛的负胎儿和儿童有关 结局包括减少胎儿生长，早产，减少出生体重，先天性缺陷，增加 新生儿医疗保健利用，并增加了以后行为的风险（例如焦虑，注意力不集中），认知 （例如，记忆缺陷，延迟语言获取）和代谢问题。尽管使用阿片类药物链接 为了不利的母亲，胎儿和儿童的结果，这些产生的机制和潜力 产前阿片类药物暴露对儿童健康和发育的后果（例如，大脑和行为）仍然存在 在很大程度上没有探索。缺乏病因学知识的治疗，预防和缓解工作有限 让个人和家庭容易回避不良后果。 健康的大脑和儿童发育（HBCD）研究是一项25个地点的纵向前瞻性研究 美国的早期儿童发育将评估广泛的生物学（例如，神经影像学，遗传学， 表观遗传学），行为（例如认知和情感调节），经验性（例如创伤），社会（例如， 种族主义）和健康（例如，心理病理学）因素，约有7,500名全国代表性的孕妇 以及他们的孩子从怀孕到儿童中期。 HBCD研究的主要目标是增加 了解产前物质暴露的潜在后果。它将为产妇而丰富 怀孕期间的药物使用（即约25％的样本将使用阿片类药物，大麻，酒精和/或 怀孕期间的烟草和总样本的12％将使用阿片类药物），并提供了独特的机会 告知我们对怀孕期间与阿片类药物使用相关的不良后果的理解 出现。尽管HBCD将是对早期大脑和儿童发育结果的最大长期研究 美国，核心方案不包括递送生物测量的收集。这种行政补充 为了回应NIDA/ORWH的行政补充特殊利益通知：Heal Initiative： 怀孕的生物循环收集（非DA-23-005）提议利用健康的脑和儿童 通过扩展核心HBCD协议的生物循环收集来开发（HBCD） 标本（胎盘，脐带组织，脐带血）。将从代表性样本中收集输送样品 HBCD研究参与者的最多14个站点（以及HBCD站点的大约2400名参与者 根据此NOSI提交申请）。这将提供前所未有的资源生成 更大的科学界有机会全面评估病理生理机制 调解怀孕期间阿片类药物和多物质使用之间的联系与不良新生儿，婴儿， 和/或孕产妇的健康成果，进而为创新的预防策略提供了信息。